Grifols, S.A.

OTCPK:GIFL.F Stock Report

Market Cap: US$7.3b

Grifols Valuation

Is GIFL.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GIFL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GIFL.F ($11.39) is trading below our estimate of fair value ($24.24)

Significantly Below Fair Value: GIFL.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GIFL.F?

Key metric: As GIFL.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GIFL.F. This is calculated by dividing GIFL.F's market cap by their current earnings.
What is GIFL.F's PE Ratio?
PE Ratio45.9x
Earnings€161.49m
Market Cap€6.90b

Price to Earnings Ratio vs Peers

How does GIFL.F's PE Ratio compare to its peers?

The above table shows the PE ratio for GIFL.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.8x
EXEL Exelixis
21.1x15.6%US$9.8b
HALO Halozyme Therapeutics
13.8x21.1%US$5.8b
ALKS Alkermes
11.5x-12.6%US$4.6b
BMRN BioMarin Pharmaceutical
36.6x27.3%US$12.1b
GIFL.F Grifols
45.9x31.3%US$6.9b

Price-To-Earnings vs Peers: GIFL.F is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the peer average (20.8x).

Price to Earnings Ratio vs Industry

How does GIFL.F's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.8x-40.6%US$8.15b
AGIO Agios Pharmaceuticals
4.5x-56.7%US$3.07b
INBX Inhibrx Biosciences
0.1xn/aUS$200.20m
CTMX CytomX Therapeutics
4.9x-35.8%US$71.22m
GIFL.F 45.9xIndustry Avg. 17.2xNo. of Companies11PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GIFL.F is expensive based on its Price-To-Earnings Ratio (45.9x) compared to the US Biotechs industry average (17.2x).

Price to Earnings Ratio vs Fair Ratio

What is GIFL.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GIFL.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GIFL.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GIFL.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.39
US$17.97
+57.8%
29.5%US$28.39US$9.46n/a13
Nov ’25US$11.05
US$18.32
+65.9%
30.7%US$29.20US$9.73n/a13
Oct ’25US$11.21
US$19.36
+72.6%
29.1%US$27.31US$9.83n/a15
Sep ’25n/a
US$19.36
0%
29.1%US$27.31US$9.83n/a15
Aug ’25n/a
US$18.97
0%
28.8%US$27.07US$9.75n/a15
Jul ’25n/a
US$18.69
0%
30.0%US$26.84US$9.66n/a16
Jun ’25US$10.68
US$19.04
+78.3%
31.0%US$27.15US$8.69n/a15
May ’25US$9.15
US$18.68
+104.2%
30.2%US$26.69US$7.47n/a14
Apr ’25n/a
US$20.25
0%
30.6%US$29.86US$7.52n/a15
Mar ’25US$9.70
US$20.46
+111.0%
27.0%US$30.13US$9.75n/a16
Feb ’25n/a
US$20.69
0%
26.3%US$30.14US$9.76n/a16
Jan ’25US$15.80
US$20.68
+30.9%
21.3%US$27.38US$13.25n/a18
Dec ’24n/a
US$20.30
0%
23.8%US$27.24US$12.08n/a17
Nov ’24US$10.50
US$19.40
+84.8%
24.2%US$26.31US$12.15US$11.0517
Oct ’24US$12.44
US$19.79
+59.1%
23.6%US$26.71US$12.29US$11.2117
Sep ’24n/a
US$19.54
0%
25.3%US$27.02US$12.43n/a17
Aug ’24US$14.20
US$19.64
+38.3%
27.7%US$27.56US$11.02n/a17
Jul ’24n/a
US$19.33
0%
28.5%US$27.26US$10.95n/a17
Jun ’24n/a
US$18.80
0%
28.3%US$26.71US$10.73US$10.6817
May ’24n/a
US$19.42
0%
32.3%US$32.91US$10.97US$9.1517
Apr ’24n/a
US$19.19
0%
31.5%US$31.90US$10.63n/a17
Mar ’24n/a
US$19.36
0%
31.0%US$31.99US$10.66US$9.7017
Feb ’24US$13.07
US$19.05
+45.8%
36.9%US$32.61US$9.78n/a17
Jan ’24n/a
US$18.22
0%
38.7%US$31.79US$9.54US$15.8017
Dec ’23n/a
US$18.69
0%
38.4%US$31.58US$9.47n/a17
Nov ’23US$8.21
US$19.81
+141.2%
34.0%US$29.89US$7.97US$10.5016

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

7D

-9.2%

1Y

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

7D

-10.5%

1Y

7.7%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

7D

-5.1%

1Y

74.5%